Complex medical decision-making and outcomes in the ICU.

Correspondence Affi liations: From the Department of Medicine (Dr Bates), McMaster University and Thrombosis and Atherosclerosis Research Institute; Faculty of Health and Life Sciences (Dr Greer), University of Liverpool; Department of Vascular Medicine (Dr Middeldorp), Academic Medical Center; Department of Pharmacy (Dr Veenstra), University of Washington; Department of Obstetrics and Gynecology (Dr Prabulos), University of Connecticut School of Medicine; and Medical Department (Dr Vandvik), Innlandet Hospital Trust and Norwegian Knowledge Centre for the Health Services. Financial/nonfi nancial disclosures: The authors have reported to CHEST the following confl icts of interest: Dr Bates has received honoraria for lectures from Leo Pharma, Inc (anticoagulant manufacturer), Sanofi -Aventis Canada (anticoagulant manufac turer), Boehringer Ingelheim GmbH (anticoagulant manufac turer), and Thrombosis Education, Ltd. Dr Greer has received honoraria for lectures and advisory board contributions from Leo Pharma and Sanofi -Aventis. Dr Middeldorp has received unrestricted research funding from GlaxoSmithKline plc and MedaPharma for the ALIFE study and has received speakers fees from GlaxoSmithKline plc; Boehringer Ingelheim GmbH; Bayer Healthcare Phar maceuticals; and Leo Pharma, Inc. Dr Vandvik is a member of and prominent contributor to the GRADE Working Group. Drs Veenstra and Prabulos have reported that no potential confl icts of interest exist with any companies/organizations whose products or services may be discussed in this article. The authors of these guidelines provided detailed confl ict of interest information which can be found online. 2